Search results for "Protocol"

showing 10 items of 1808 documents

Can We Improve the Evaluation of Cardiovascular Risk in Obese Children? A Possible Study Protocol

2020

Abstract The link between obesity and a wide range of cardiovascular disorders is well known.(1,2) In recent years, the prevalence of obesity has reached an alarming level.(3) Unfortunately, the situation is similar for the paediatric population – which may provide a perspective on the continuously growing global burden of this affliction.(4) Acting upon this issue is a fundamental direction in modern preventive medicine. A firm action starting in childhood may prove itself to be more beneficial the sooner it is implemented. Multiple anthropometric, clinical, laboratory and imaging parameters have been related to the presence of obesity and cardiovascular risk. This article represents a pro…

0301 basic medicineProtocol (science)03 medical and health sciencesmedicine.medical_specialty030104 developmental biology0302 clinical medicinebusiness.industryMedicineGeneral Medicine030204 cardiovascular system & hematologybusinessIntensive care medicineActa Medica Transilvanica
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysi…

2020

Abstract Objectives To evaluate the effectiveness and safety of nintedanib plus docetaxel in patients with advanced adenocarcinoma non-small cell lung cancer (NSCLC) previously treated with both chemo- and immunotherapy. Materials and methods LUME-BioNIS is a European, prospective, multicenter, non-interventional study of patients with advanced adenocarcinoma NSCLC, who initiated nintedanib plus docetaxel after first-line chemotherapy in routine practice according to the approved nintedanib EU label. The primary objective is to explore whether molecular biomarkers can predict overall survival (OS). Information on clinical or radiologic progression and death, and adverse drug reactions (ADRs…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung Neoplasmsmedicine.medical_treatmentSubgroup analysisPembrolizumabDocetaxelAdenocarcinoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtezolizumabInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesLung cancerChemotherapybusiness.industrymedicine.disease030104 developmental biologyTreatment OutcomeOncologychemistryDocetaxel030220 oncology & carcinogenesisNintedanibTaxoidsImmunotherapyNivolumabbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

2018

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibody is approved for the treatment of relapsed and/or refractory (RR) MM in combination with lenalidomide and dexamethasone. Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcγRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Interestingly, SLAMF7 is also expressed on cytolytic NK cells, which also expr…

0301 basic medicineReviewNK cellsLymphocyte ActivationDexamethasoneMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyElotuzumabLenalidomideMultiple myelomaAntibody-dependent cell-mediated cytotoxicityBortezomibSLAMF7ADCPPlasma cell neoplasmelotuzumab3. Good healthmultiple myelomaKiller Cells Naturalmedicine.anatomical_structureNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisSLAMF7ADCCmedicine.druglcsh:Immunologic diseases. AllergyImmunologyPlasma CellsAntineoplastic AgentsmacrophageAntibodies Monoclonal HumanizedGPI-Linked Proteins03 medical and health sciencesPhagocytosisSignaling Lymphocytic Activation Molecule FamilymedicineBiomarkers TumorAnimalsHumansbusiness.industryNatural Cytotoxicity Triggering Receptor 1MacrophagesReceptors IgGNKG2Dmedicine.disease030104 developmental biologyCancer researchBone marrowbusinesslcsh:RC581-607Transcription FactorsFrontiers in Immunology
researchProduct

Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity

2017

Abstract Purpose: Neuroblastoma is a pediatric tumor of peripheral sympathoadrenal neuroblasts. The long-term event-free survival of children with high-risk neuroblastoma is still poor despite the improvements with current multimodality treatment protocols. Activated JAK/STAT3 pathway plays an important role in many human cancers, suggesting that targeting STAT3 is a promising strategy for treating high-risk neuroblastoma. Experimental Design: To evaluate the biologic consequences of specific targeting of STAT3 in neuroblastoma, we assessed the effect of tetracycline (Tet)-inducible STAT3 shRNA and the generation 2.5 antisense oligonucleotide AZD9150 which targets STAT3 in three representat…

0301 basic medicineSTAT3 Transcription FactorCancer Researchmedicine.disease_causeSmall hairpin RNA03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomaCell Line TumorOligonucleotidemedicineSTAT3CarcinogenesiCell ProliferationCisplatinAntineoplastic Combined Chemotherapy ProtocolbiologyCell growthAnimalCancerApoptosiOligonucleotides Antisensemedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation Neoplastic030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisCancer researchbiology.proteinCisplatinCarcinogenesismedicine.drugHuman
researchProduct

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal c…

2019

Abstract Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor activities with promising perspectives in cancer immunotherapy. In this context, Vδ2pos T cells represent the preferential target of several immunotherapy protocols against solid tumors. However, the impact of both aging and chemotherapy (CHT) on Vδ2pos T cells is still unknown. The present study evaluates with multi-parametric flow cytometry the frequencies, terminal differentiation, senescence and effector-functions of peripheral blood and tumor infiltrating Vδ2pos T cells purified from liver metastases (CLM) of patients affected by colorectal cancer (CRC) compared to …

0301 basic medicineSenescenceCancer ResearchColorectal cancermedicine.medical_treatmentImmunologyShort ReportContext (language use)Antineoplastic AgentsCD16lcsh:RC254-282γδ T cellsFlow cytometryImmunophenotyping03 medical and health sciences0302 clinical medicineCancer immunotherapyT-Lymphocyte SubsetsCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineImmunology and AllergyChemotherapyHumansCellular SenescenceCancerPharmacologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCD28Receptors Antigen T-Cell gamma-deltaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistry030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMolecular MedicineImmune-senescence/AgingbusinessColorectal NeoplasmsBiomarkersJournal for Immunotherapy of Cancer
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

Reference genome assessment from a population scale perspective: an accurate profile of variability and noise.

2017

Abstract Motivation Current plant and animal genomic studies are often based on newly assembled genomes that have not been properly consolidated. In this scenario, misassembled regions can easily lead to false-positive findings. Despite quality control scores are included within genotyping protocols, they are usually employed to evaluate individual sample quality rather than reference sequence reliability. We propose a statistical model that combines quality control scores across samples in order to detect incongruent patterns at every genomic region. Our model is inherently robust since common artifact signals are expected to be shared between independent samples over misassembled regions …

0301 basic medicineStatistics and ProbabilityQuality ControlGenotypeComputer sciencemedia_common.quotation_subjectPopulationGenomicsBioinformaticscomputer.software_genreBiochemistryGenome03 medical and health sciencesGenetic variationAnimalsHumansQuality (business)AlleleeducationMolecular BiologyGenotypingReliability (statistics)media_commonProtocol (science)education.field_of_studyGenomeModels StatisticalGenetic VariationReproducibility of ResultsGenomicsGenome AnalysisOriginal PapersComputer Science ApplicationsComputational Mathematics030104 developmental biologyComputational Theory and MathematicsData miningcomputerSoftwareReference genome
researchProduct

Robust Analysis of Time Series in Virome Metagenomics

2018

Metagenomics is a powerful tool for assessing the functional and taxonomic contents in biological samples as it makes feasible to study, simultaneously, the whole living community related to a host organism or medium: all the microbes, including virus, bacteria, archaea, fungi, and protists. New DNA and RNA sequencing technologies are dramatically decreasing the cost per sequenced base, so metagenomic sequencing is becoming more and more widespread in biomedical and environmental research. This is opening the possibility of complete longitudinal metagenomic studies, which could unravel the dynamics of microbial communities including intra-microbiome and host-microbiome interactions through …

0301 basic medicinebiologySeries (mathematics)Computer scienceFrame (networking)RNAComputational biologybiology.organism_classification03 medical and health scienceschemistry.chemical_compound030104 developmental biologyMicrobial population biologychemistryMetagenomicsHuman viromeRobust analysisProtocol (object-oriented programming)CoevolutionBacteriaDNAArchaea
researchProduct